A downtrend has been apparent in Cassava Sciences, Inc. (SAVA) lately with too much selling pressure. The stock has declined ...

(Reuters) -Cassava Sciences said on Tuesday its Alzheimer's drug simufilam, which has been at the center of regulatory scrutiny, failed in a second late-stage study, sending shares of the company down ...

Cassava Sciences, Inc.’s SAVA share price has dipped by 20.00%, which has investors questioning if this is right time to buy.

While investigations into the drug are stopping in Alzheimer’s disease, the therapy is now being evaluated in TSC-related epilepsy.

Cassava said that it will discontinue all efforts to develop simufilam and expects to phase out the program by the end of the second quarter. Still, the biotechnology company said it has begun ...

Cassava Sciences is ending simufilam development for Alzheimer's after Phase 3 trials failed. The company is shifting focus to potential seizure treatments.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In this article, we are going to take a look at where Cassava Sciences, Inc. (NASDAQ:SAVA) stands against other best short-term stocks with a buying opportunity for investors. Thrilling highs ...

Cassava Sciences will discontinue its potential Alzheimer's treatment after recent trials showed no improvement to cognitive or functional decline. Shares halted from trading ahead of the morning ...

Write to [email protected] Cassava Sciences NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

Simufilam continued to demonstrate an overall favorable safety profile. About REFOCUS-ALZ Cassava Sciences NewsMORE Related Stocks ...